Burning Rock Biotech (NASDAQ:BNR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Burning Rock Biotech (NASDAQ:BNR) to a hold rating in a report published on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings raised shares of Burning Rock Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Burning Rock Biotech Stock Performance

Burning Rock Biotech stock opened at $11.15 on Friday. The business’s fifty day moving average is $13.10 and its two-hundred day moving average is $16.72. The firm has a market cap of $117.30 million, a P/E ratio of -12.82 and a beta of 1.29. Burning Rock Biotech has a 52 week low of $6.79 and a 52 week high of $41.72.

Burning Rock Biotech (NASDAQ:BNR) last released its quarterly earnings results on Thursday, September 10th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($2.29) by $2.09. The business had revenue of $19.84 million for the quarter, compared to analysts’ expectations of $19.21 million. Burning Rock Biotech had a negative net margin of 13.60% and a negative return on equity of 12.98%.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Burning Rock Biotech stock. Renaissance Technologies LLC lifted its stake in shares of Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) by 13.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 35,407 shares of the company’s stock after purchasing an additional 4,290 shares during the period. Renaissance Technologies LLC owned 0.34% of Burning Rock Biotech worth $571,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech Limited is a biotechnology company focused on precision oncology. The company develops and commercializes next-generation sequencing (NGS) tests designed to help detect cancer, guide treatment decisions and monitor patients during therapy.

Its offerings include tissue- and blood-based genomic testing for cancer patients, as well as tests intended to support therapy selection, treatment monitoring and the identification of biomarkers relevant to targeted medicines and immunotherapies.